FOXO's healthcare acquisitions boost revenue but leave $30.6M working-cap deficit

Snapshot - what's happening inside FOXO Technologies Inc. (NASDAQ: DWIN)

FOXO expanded into healthcare via the Myrtle and RCHI acquisitions (mid‑2024), which drove a material jump in reported revenue in Q1 2025 but left the company with a stretched balance sheet, heavy short‑term liabilities and a restatement related to acquisition measurement‑period consideration. Management recorded a $5,132,928 adjustment to goodwill and a payable to RHI, and continues to disclose substantial going‑concern risk.

Key facts & statistics (as reported for the three months ended March 31, 2025)

- Net revenues: $3,169,920 (prior period: $7,180)

- Net loss, including noncontrolling interest: $(620,808)

- Net loss attributable to FOXO: $(616,458)

- Net loss to common stockholders, net of undeclared preferred dividends: $(1,103,492)

- Loss from operations: $(1,546,980)

- Total operating expenses: $4,716,900 (Direct costs: $1,903,936; R&D: $30,000; SG&A: $2,764,086)

- Gain from extinguishment of Senior PIK Notes (non‑cash): $1,863,834

- Interest expense: $(889,792)

- Cash and cash equivalents at period end: $16,907

- Net cash used in operating activities (Q1): $(1,337,591)

- Accounts receivable, net: $2,654,901 (gross AR: $15,739,334; allowance for contractual obligations: $(12,044,229); allowance for doubtful accounts: $(1,040,204))

- Goodwill: $30,596,876 (increase includes $5,132,928 measurement‑period adjustment)

- Total current liabilities: $33,790,593

- Working capital deficit: $(30,595,902)

Positive (income‑statement) takeaways

- Revenue scale appeared: Net revenues rose to $3.17M in Q1 2025 (from $7,180) - driven by the Healthcare segment (Myrtle + RCHI produced $3,161,431 of the quarter's revenue).

- Non‑cash accounting gain improved the headline loss: the $1.863M gain from extinguishing Senior PIK Notes materially reduced net loss for the period.

- Loss narrowed year‑over‑year at the FOXO level: net loss attributable to FOXO improved vs Q1 2024 ($(616,458) vs $(1,503,990)), in part because of the PIK Notes gain.

Negative (income‑statement & related) points - material and persistent

- Operating loss remains: loss from operations was $(1,546,980) driven by high SG&A and direct costs tied to the new healthcare operations.

- Heavy interest burden: interest expense of $(889,792) in one quarter - driven by many short‑term and high‑cost notes - increases cash strain.

- Large contractual allowances wipe down revenue recognition: $12,044,229 recorded as contractual allowances plus $1,040,204 doubtful accounts, leaving only $2.65M net AR from $15.74M gross.

- Cash burn + near‑zero cash: Q1 operating cash use $(1.34M) and only $16,907 cash on hand at quarter end - severe short‑term liquidity risk.

- Working capital and leverage: $33.79M current liabilities and a $(30.6M) working capital deficit - the company must raise or restructure financing to operate.

- Accounting restatement / measurement‑period adjustment: $5,132,928 of additional purchase price consideration for RCHI was recorded as goodwill and a related payable to RHI (filed in Form 10‑Q/A); while the restatement did not change operating results, it increased liabilities and goodwill materially.

Other operational highlights that affect the P&L and outlook

- Segment mix: Healthcare now produces almost all revenue (Healthcare: $3,161,431; Labs & Life: $8,489). Labs revenue remains immaterial.

- Non‑recurring items skew results: several sizable non‑operating and financing transactions (note exchanges, preferred issuances, deemed dividends and warrant revaluations) materially affect reported loss and equity balances.

- Equity & dilution complexity: multiple preferred series, convertible notes, assumed warrants and anti‑dilution triggers create potential future dilution and periodic non‑cash deemed dividends that hit retained earnings/communicated net loss to common holders.

Bottom line / straight answer

FOXO (NASDAQ: DWIN) shows meaningful revenue after integrating Myrtle and RCHI, but the income statement improvement is largely driven by a one‑time, non‑cash gain from extinguishing PIK notes. Under the surface, operating losses, high interest expense, massive receivable allowances, near‑zero cash ($16,907) and a $30.6M working capital deficit create acute liquidity and going‑concern risk. Management must secure financing or materially improve operating cash flow to avoid further distress.

If you want, I can draft a one‑page investor summary (pros/cons + recommended next‑step questions for management or creditors) or extract a short list of red flags and catalysts to watch over the next 90 days.